Abeona Therapeutics Inc vs Essex Property Trust, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while Essex Property Trust, Inc. trades at $280.01 (market cap $18.15B). The key difference: Essex Property Trust, Inc. is far larger — about 43.1× Abeona Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ESS | |
|---|---|---|
Market Cap | $421.19M | $18.15B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $298.33 |
52-Week Low | $4.17 | $239.61 |
Enterprise Value | $276.10M | $24.75B |
Dividend Yield | — | 3.93% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ESS trades at $282.11, down 0.39% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 EPS of $0.97, missing expectations, but raised full-year guidance after strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is trending lower in 2026. Recent news includes ESS being named a top GreenTech company and signing a 500 MWh energy storage agreement with Juniper Energy.
The outlook is mixed: raised guidance and institutional buying support upside, but technical weakness and earnings miss pose near-term risks. Valuation ratios like P/E of 19.9 and P/S of 9.05 are reasonable for a REIT, yet debt levels and regional market volatility require caution. Analyst consensus is a Moderate Buy with a $305.86 price target, suggesting 8.4% potential upside from current levels.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →